By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


New Haven Pharmaceuticals 

P.O. Box 586

Guilford  Connecticut  06437  U.S.A.
Phone: 770-329-0074 Fax: n/a



Company News
New Haven Pharmaceuticals Presents Survey Results That Showed High Risk Cardiovascular Patients Believed That There Are Generally Greater Benefits Associated With Prescription Versus OTC Medications 3/8/2016 6:17:16 AM
New Haven Pharmaceuticals Presents Positive Data That Shows DURLAZA Is Well Tolerated And Delivers Sustained 24-Hour Antiplatelet Control 3/1/2016 1:14:05 PM
New Haven Pharmaceuticals Announces Availability of DURLAZA, First And Only Once-Daily 24-Hour Aspirin 1/8/2016 6:55:02 AM
New Haven Pharmaceuticals President Named 2015 Entrepreneur Of The Year By Connecticut United For Research Excellence (CURE) 12/16/2015 9:39:28 AM
New Haven Pharmaceuticals: Study Shows DURLAZA (aspirin) Extended-Release Capsules Delivers Sustained Antiplatelet Effects For Full 24 Hours 11/10/2015 9:49:53 AM
New Haven Pharmaceuticals To Share DURLAZA (aspirin) Extended-Release Capsules Study Data At American Heart Association Scientific Sessions Fall Event 11/2/2015 10:19:41 AM
New Haven Pharmaceuticals Receives FDA Approval For DURLAZA (Aspirin) Extended Release Capsules For Secondary Prevention Of Stroke And Acute Cardiac Events 9/8/2015 9:32:41 AM
New Haven Pharmaceuticals Expands Management Team With Two Senior-Level Appointments 10/8/2014 10:43:29 AM
New Haven Pharmaceuticals Appoints Larry Dillaha, M.D. As Executive Vice President Operations 4/2/2014 6:36:01 AM
Connecticut Innovations Makes Follow-On Investment In New Haven Pharmaceuticals 1/30/2014 9:18:55 AM